Press Releases for QLTI

Press Releases
QLT Acquires Early-Stage Ophthalmic Asset for US$7.5 Million
QLT Announces Receipt of a CDN$45.3 Million Tax Refund
QLT Announces Second Quarter Results for 2009
QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
Zymeworks Closes $3.5 Million Round of Financing and Announces Changes to Its Board of Directors
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
QLT announces positive results from the evaluation of Visudyne(R) combination therapy
QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
QLT Announces First Quarter Results for 2009
QLT Names Kathryn Falberg to the Board of Directors
QLT names Kathryn Falberg to the board of directors
QLT announces completion of Phase Ia safety trial of its synthetic retinoid product
QLT petition for rehearing of Massachusetts Eye and Ear Infirmary litigation is denied - PR Newswire
QLT petition for rehearing of Massachusetts Eye and Ear Infirmary litigation is denied - CNW
QLT Announces Fourth Quarter and Year End 2008 Results
QLT Announces Fourth Quarter and Year End 2008 Results
QLT announces that it is named as a defendant in an action - PR Newswire
QLT announces that it is named as a defendant in an action - CNW
QLT announces final results of tender offer
QLT announces final results of tender offer
QLT announces preliminary results of tender offer
QLT announces preliminary results of tender offer
QLT announces new expiration date of tender offer
QLT announces new expiration date of tender offer
QLT Announces Appeal Court Decision on Massachusetts Eye and Ear Infirmary Litigation
QLT Announces Appeal Court Decision on Massachusetts Eye and Ear Infirmary Litigation
QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008
QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008
QLT announces interim results of radical study evaluating Visudyne combination therapy
QLT announces interim results of radical study evaluating Visudyne combination therapy
QLT announces commencement of tender offer
QLT announces commencement of tender offer
QLT to repurchase up to US$ 50 million of common shares - Modified "Dutch Auction" tender offer to commence on or about December 4, 2008
QLT to repurchase up to US$ 50 million of common shares - Modified "Dutch Auction" tender offer to commence on or about December 4, 2008
QLT announces third quarter results for 2008
QLT announces third quarter results for 2008
QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
QLT announces third quarter 2008 Visudyne(R) sales
QLT announces third quarter 2008 Visudyne(R) sales
QLT announces the initiation of a Phase I trial of its synthetic retinoid product
QLT announces the initiation of a Phase I trial of its synthetic retinoid product
QLT announces completion of the redemption of 3% Convertible Senior Notes due 2023
QLT announces completion of the redemption of 3% Convertible Senior Notes due 2023
QLT completes Cdn$65.5 million real estate transaction
QLT completes Cdn$65.5 million real estate transaction
QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. - CNW
QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. - PR Newswire
QLT announces redemption of 3% convertible senior notes due 2023
QLT announces redemption of 3% convertible senior notes due 2023
QLT announces removal of conditions on Cdn$65.5 million real estate transaction
QLT announces removal of conditions on Cdn$65.5 million real estate transaction
QLT announces second quarter results for 2008
QLT announces second quarter results for 2008
QLT announces second quarter 2008 Visudyne(R) sales
QLT announces second quarter 2008 Visudyne(R) sales
Allergan Completes Acquisition of Aczone Gel 5%
QLT completes divestment of Aczone(R) to Allergan for USD$150 million
QLT completes divestment of Aczone(R) to Allergan for USD$150 million
Allergan Announces Agreement to Acquire Aczone(R) Gel 5%
QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million
QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million
QLT announces positive Health Canada decision on Aczone(R)
QLT announces positive Health Canada decision on Aczone(R)
QLT Inc. announces agreement for sale of real estate - Jun 2 2008 2:22AM
QLT Inc. announces agreement for sale of real estate - May 27 2008 12:55AM
QLT Inc. announces agreement for sale of real estate - May 27 2008 12:55AM
QLT reports initial proof of concept data for punctal plug delivery technology - Jun 2 2008 2:22AM
QLT completes enrollment in the RADICAL study
QLT announces first quarter results for 2008
QLT announces first quarter 2008 Visudyne(R) sales